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Early in mammalian development, the stem cell leukemia
(SCL/TAL1) gene and its distinct 30 enhancer (SCL 30En)
specify bipotential progenitor cells that give rise to blood and
endothelium, thus termed hemangioblasts. We have previously
detected a minor population of SCL (þ ) cells in the postnatal
kidney. Here, we demonstrate that cells expressing the
SCL 30En in the adult kidney are comprised of CD45þ
CD31 hematopoietic cells, CD45CD31þ endothelial cells
and CD45CD31 interstitial cells. Creation of bone marrow
chimeras of SCL 30En transgenic mice into wild-type hosts
shows that all three types of SCL 30En-expressing cells in the
adult kidney can originate from the bone marrow. Ischemia/
reperfusion injury to the adult kidney of SCL 30En transgenic
mice results in the intrarenal elevation of SCL and FLK1 mRNA
levels and of cells expressing hem-endothelial progenitor
markers (CD45, CD34, c-Kit and FLK1). Furthermore, analysis
of SCL 30En in the ischemic kidneys reveals an increase in the
abundance of SCL 30En-expressing cells, predominantly within
the CD45 (þ ) hematopoietic fraction and to a lesser extent in
the CD45 () fraction. Our results suggest organ-injury-induced
reactivation of bone marrow-derived hemangioblasts and
possible local angioblastic progenitors expressing SCL and
SCL 30En.
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Introduction
The vascular system develops in close association with the
hematopoietic lineage in vertebrate embryos. Vasculogenesis
refers to in situ formation of primitive blood vessels from
endothelial precursors or angioblasts.1 Endothelial precursor
cells have been identified in adult bone marrow and peripheral
blood.2,3 These endothelial precursor cells have been shown to
share properties with embryonic angioblasts;4,5 they have the
capacity to migrate, proliferate and differentiate in situ into
mature endothelial cells and to colonize sites of active
neovascularization.
Despite recent progress in the identification of signaling
molecules and cell surface receptors that regulate blood vessel
formation, little is currently known about the precise transcrip-
tional events that govern endothelial fate. The stem cell
leukemia (SCL) gene (also known as TAL1) encodes a basic
helix–loop–helix protein that is commonly activated in T-cell
leukemia.6 SCL was found to be essential for normal embryonic
and definitive hematopoiesis as well as for proper vascular
development;7–10 SCL-deficient mice die in utero between E9.5
and 10.5 with no evidence of blood formation and with a severe
defect in vascular development.9,10 SCL is also important for the
commitment of the common precursor of both hematopoietic
and endothelial lineages, the hemangioblast. During embryo-
genesis, SCL is one of the first markers detected in isolated
mesodermal cells that give rise to angioblasts while its
expression is downregulated in the endothelium of mature
vessels.11,12 In zebrafish development, SCL is expressed in a
population of putative hemangioblasts. Ectopic SCL expression
greatly increased the number of hemangioblasts and also
resulted in excessive blood and endothelial development at
the expense of other mesodermal cell fates.13 In this model
organism, SCL (þ ) progenitors ultimately migrate and localize
to the kidney, the definitive site of hematopoiesis.14 More recent
studies have shown a combined critical role for FLK-1, a
receptor tyrosine kinase (VEGFR2), and SCL, in hemangioblast
specification.15,16 Specifically, it was suggested that specifica-
tion within FLK-1-expressing mesoderm is regulated by SCL
expression.17,18 Importantly, FLK-1-expressing mesoderm con-
tributes to the circulatory system including vasculogenesis of the
embryonic kidney.19
A 30 element (the 5245 bp SCL þ 18/19 enhancer or SCL 30En)
localized 19 kb downstream of exon 1 of the SCL gene has a
remarkable specificity in regulating SCL expression in the
hematopoietic and angioblastic compartments.20,21 Within this
fragment, a 644 bp core þ 19 enhancer was subsequently
defined and shown to be active at a single time point in
embryonic blood and endothelium.22 During embryonic deve-
lopment, the SCL 30En is selectively active in a subset of
mesodermal cell lineages, including endothelial and hemato-
poietic stem cells and progenitors.20,21 These cells express c-Kit
and CD34, both associated with hematopoietic progenitors. In
adult mice, the 30En is active in the vast majority of
hematopoietic stem cells and progenitors present in bone
marrow20 and recent evidence suggests also expression in some
adult endothelial cells.23 Unlike the þ 18/19 enhancer whose
activity was assessed in transgenic mice carrying a LacZ/þ 18/
19 reporter construct, the þ 19 core enhancer was active only in
adult mice when linked to the eukaryotic reporter gene human
placental alkaline phosphatase (PLAP)23.
We have recently shown that SCL expression and the activity
of the SCL 30En are developmentally regulated in the mamma-
lian kidney.24 The early and specific expression of SCL 30En in
the metanephric mesenchyme suggests a role in the differentia-
tion and growth of the mammalian kidney, especially in
specifying angioblastic progenitors. Interestingly, although
postnatal SCL message was abrogated, we observed SCL 30En
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(þ ) cells resident in the adult kidney.24 Renal developmental
pathways have been shown to be activated during adult tissue
regeneration,25,26 providing possible links for both processes.
In addition, blood and marrow-derived cells have been
recently suggested to have vasculogenic potential during
kidney damage.27,28 We have therefore hypothesized that
the expression of SCL characterizing embryonic kidney
will re-appear during regeneration of adult kidney integrating
bi-potential information needed for blood and endothelial
development.
Methods
Animals
All mice used were of the (CBAC57BL/6) background.
SV/PLAP/19 transgenic mice expressing the human alkaline
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phosphatase gene under the regulatory elements of the SCL 30En
(þ 19 region) and SCL þ 6E5/lacZ/30En transgenic mice (þ 18/
19 region) were described previously.20–23 A breeding pair of
þ 6E5/lacZ/30En transgenic mice was kindly provided by AR
Green, Cambridge Institute for Medical Research. Mice were
placed under conventional housing and diet in a pathogen-free
(SPF) environment. All animal procedures were approved by the
local committee for care and use of laboratory animals and were
performed according to governmental and international guide-
lines on animal experimentation.
Newborn transplantation assays
To generate chimeric mice we followed the protocol published
by Yoder et al.29 with modifications. In brief, pregnant females
are injected with busulfan (Sigma-Aldrich, St Louis, MO, USA)
to sublethally condition the newborn pups for high-level donor
cell engraftment. Busulfan is prepared at 1 mg ml1 in 2%
dimethylsulfoxide in phosphate-buffered saline (PBS). The
pregnant dam is given an intraperitoneal injection of
15.5 mg kg1 of busulfan on the morning of days 17 and 18 of
pregnancy. Pups are born on day 19 and injected in the facial
vein on day 20 according to the protocol described by Sands
and Barker.30
Bone marrow cells were obtained from SCL-þ 19 PLAP
transgenic mice and prepared as previously described.23 Bone
marrow cells (5 106 cell) suspension is injected in 50 ml of D-
PBS 1% fetal calf serum. When primary recipient animals have
reached 1 month of age, blood is retrieved from the tail and
subject to PLAP-PCR blood chimerism analysis. Positive
chimeras are killed between 4 and 6 months. For fluore-
scence-activated cell sorting (FACS) analysis, bone marrow cells
from transgenic mice were stained according to the protocol
described in the following section as previously described.23
Cells were stained with the antibodies PLAP, Ter119PE, CD45PE
and CD31bio followed by incubation with anti-rabbit-FITC and
stretavidine-cy5.
Hematopoietic chimerism analysis
To test the contribution of donor hematopoietic stem cells to
different hematopoietic lineages, long-term transplanted mice
were killed at 4–6 months post transplant. A week before killing,
peripheral blood was drawn from the tail of the recipient mice
into 0.3% EDTA in PBS and red blood cells lysed with Tris-
buffered ammonium chloride (9:1 dilution of 0.16 M NH4Cl/
0.17 M Tris pH 7.6). Leukocytes were pelleted, stained for PLAP
(AbD Serotec, Oxford, UK) and CD45-PE (clone 30-F11, BD
Biosciences Pharmingen, San Jose, CA, USA) followed by
incubation with sheep anti-rabbit biotin-conjugated antibody
(AbD Serotec) and streptavidin-FITC conjugate (BD Biosciences
Pharmingen). Cells were analyzed by flow cytometry (FACS)
using a FACSAria flow cytometer (BD Biosciences) according to
the protocol previously described.23 Peripheral blood chimerism
was assessed by quantification of the percentage of PLAPþ cells
compared to the levels in SV/PLAP/19 transgenic and nontrans-
genic mice. To confirm multilineage hematopoietic engraft-
ment, animals with high levels of peripheral blood PLAPþ cells
were killed and genomic DNA was isolated from spleen, lymph
nodes, thymus and bone marrow or FACS-sorted cells and
analyzed by PCR for the presence of the PLAP transgene as
published.23
Ischemia/reflow experiments
Eight-week-old SCL þ 6E5/lacZ/30En transgenic mice were used
for ischemia/reperfusion (I/R) injury according to the protocol
previously described.31 Mice were anesthetized with
100 mg kg1 ketamine and 10 mg kg1 xylazine injected in-
traperitoneally, and a flank incision was made. For unilateral
I/R, the left renal pedicle was clamped for 40 min using a
vascular clamp (Fine Science Tools Inc., Foster City, CA, USA).
The abdomen was covered with gauze moistened in PBS, and
the mice were maintained at 371C using a warming pad. After
40 min, the clamp was removed and reperfusion was confirmed
visually. Mice were killed at 24 h, 48 h, 1 week, 2 weeks and 4
weeks after injury was performed and kidneys were processed
for histological (hematoxylin and eosin and sirius red staining)
and molecular analysis.
Flow cytometry of renal cells
Intact and ischemic kidneys were washed extensively with
sterile PBS to remove contaminating debris and red blood cells.
Kidneys were then diced and treated with 0.075% collagenase
(type D; Sigma-Aldrich, St Louis, MO, USA) diluted in PBS for
60 min at 371C with gentle agitation. The collagenase was
inactivated with an equal volume of culture medium (DMEM/
10% fetal calf serum/1% penicillin–streptomycin), the dissolved
tissue further minced and then centrifuged for 10 min at low
speed. The cellular pellet was resuspended in culture medium
and sequentially filtered through 70 and 40 mm mesh filters to
remove debris and cell segments. Cell suspensions were treated
with cold ACK buffer (0.15 M potassium-ammonium chloride
buffer) to remove remaining red blood cells. Flow cytometric
analysis was performed using a modified FACScan (BD
Figure 1 Analysis of bone marrow-derived chimeras. Newborn mice were transplanted with total bone marrow cells derived from SV/PLAP/þ19
transgenic mice and high-level reconstituted chimeric mice analyzed at 4–6 months post transplant. (a) Flow cytometric profiles of peripheral
blood are shown for CD45 and hPLAP expression for transgenic, nontransgenic and chimeric mice. All PLAPþ cells coexpress CD45. (b) Flow
cytometric profiles of bone marrow are shown for CD45/Ter119, hPLAP and CD31 expression for nontransgenic and transgenic mice. Expression
of CD31 in the gated PLAPþCD45Ter119 population is represented in the histogram. Percentages of total cells (106 events) are shown in each
quadrant. Percentage of cells out of the gated PLAPþCD45Ter119 population is shown in the histogram. (c) Histochemical detection of hPLAP
activity (purple stain) in paraffin sections of kidney derived from nontransgenic, transgenic and chimeric mice. Expression is detected in the
vascular network of transgenic mice and cells with endothelial and fibroblastic appearance in the chimera. (d) Immunofluorescence images of
kidney sections from SV/PLAP/þ 19 PLAP transgenic (upper panel) and SV/PLAP/þ19 bone marrow-derived chimeric mice (lower panel) co-
stained with anti-PLAP (red), anti-CD45 (green) and anti-CD31 (blue) antibodies. Three types of cell are identified in the merged image:
PLAPþCD45CD31 (arrows), PLAPþCD45CD31þ (asterisk), PLAPþCD45þCD31 (arrowheads). (e) Immunofluorescence images of
liver sections from SV/PLAP/þ 19 PLAP transgenic (upper panel) and SV/PLAP/þ 19 bone marrow-derived chimeric mice (lower panel) co-stained
with anti-PLAP (red), anti-CD45 (green) antibodies and isolectine B4 (blue). Two types of cells are identified in the merged image of chimeric liver:
PLAPþCD45CD31þ (asterisk) and PLAPþCD45þCD31 (arrowheads). PLAP, placental alkaline phosphatase.
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Biosciences). Fluorescence data were collected using 3-decade
logarithmic amplification on 25–50 103 viable cells, as
determined by forward light scatter intensity. Cells were labeled
with CD45, CD34, c-Kit- and Flk-1-PE (BD Pharmingen).
PE-rat IgG2a was used as isotype control.
Real-time PCR
cDNA was synthesized using Omniscripts Reverse Transcrip-
tase (Qiagen, Hilden, Germany) on total RNA. Real-time PCR of
mouse samples was performed using an ABI7900HT sequence
detection system (Perkin-Elmer/Applied Biosystems, Foster City,
CA, USA) in the presence of SYBR-green (SYBR green PCR kit;
Qiagen). This fluorochrome incorporates stoichiometrically into
the amplification product, providing real-time quantification of
double-stranded DNA PCR product. The following primers
were designed, to amplify an 80–120 bp fragment with 50–65 1C
annealing temperature: FLT1, 50-AAGCGGTTCACCTGGACT
GA-30 and 50-CCTTGCTTTTACTCGCTATTCTCA-30; FLK1, 50-GTG
GTCTTTC GGTGTGTTGCT-30 and 50-TCTCCTACAAAATT
CTTCATCAATCTTG-30; SCL, 50-CATGTTCACCAACAACAA
CCG-30 and 50-GGTGTGAGGACCATCA GAAATCTC-30;
b-actin, 50-CCTGTATGCCTCTGGTCGTA-30 and 50-CCATCTCC
TGCTCGAAGTCT-30. The relative initial amount of mRNA of a
particular gene was extrapolated from a standard curve. For
standard curve determination, we used a pool of all the samples,
serially diluted in four log2 steps and run in parallel to the
samples. The total volume of each reaction was 20 ml, contain-
ing 300 nM of each forward and reverse primer and 125 ng
of cDNA. Appropriate negative controls were run for each
reaction. All of the reactions were performed in triplicate.
Optimization of the real-time PCR reaction was performed
according to the manufacturer’s instructions. For each analysis,
transcription of the gene of interest was compared with
transcription of the housekeeping gene b-actin.
Immunohistochemistry
Animals were perfused with Tris-buffered saline and tissues
placed in zinc fixative (BD Pharmingen, San Diego, CA, USA)
for 72 h, dehydrated in ethanol series, cleared in xylene,
processed into paraffin wax at 601C for a total of 40 min and
embedded. Sections (5–6 mm) were placed on electrostatically
charged slides (VWR International) and rehydrated. Histochem-
ical detection of PLAP in tissue sections was performed as
described.23 For inhibition of endogenous phosphatases, the
sections were incubated in pre-heated PBS at 751C for 35 min.
After a 10-min wash in AP buffer (0.1 M Tris-HCl pH 9.5, 0.1 M
MgCl2, 0.1 M NaCl), the slides were transferred into AP staining
solution (0.1 M Tris-HCl pH 9.5, 0.05 M MgCl2, 0.1 M NaCl and
BCIP/NBT substrate, Roche, Basel, Switzerland) and incubated
in the dark at room temperature for 1 h. Tissue sections were
counterstained with brazilin (Anachem, Luton, UK), dehydrated
in ascending concentrations of ethanol, cleared in PronaHisto-
clear II (Pronadisa, National Diagnostics) and mounted in DPX
(BDH, VWR Poole, UK). For immunofluorescence staining, after
re-hydration 5 mm sections were blocked with 20% goat serum
for 2 h followed by incubation with rabbit anti-PLAP (1:10
dilution; AbD Serotec) and rat anti-CD31 antibodies (1:20
dilution; BD Biosciences), followed by anti-rabbit Alexa 568
(1:500) and anti-rat Alexa 647 (1:500) (Invitrogen Molecular
Probes, Eugene, OR, USA). After several washes in PBS, slides
were fixed in neutral-buffered formalin 4% (Merck, Darmstadt,
Germany) for 5 min, washed and incubated with rat anti-CD45
(BD Biosciences), followed by staining with anti-rat Alexa 488.
All primary antibody incubations were performed for 2 h and
secondary antibody incubations for 1 h. IsolectineB4 was also
used for endothelial staining. Tissue sections were stained
overnight with biotinylated isolectineB4 B4 (L2140; Sigma)
followed by incubation with streptavidin Cy5.32 Controls were
performed by omitting the primary antibody at different steps of
the staining procedure. Immunofluorescence image analysis was
performed using a Delta Vision system with an Olympus IX-71
microscope (Applied precision; Issaquah, WA, USA). Halogen
lamp and appropriate filter combinations were used (excitation
filters 470/40, 555/28 and 640/20; emission filters 528/38,
617/73 and 685/40). The images were taken using a UPLAN FL
N  40/1.30 oil objective).
For detection of SCL lacZ/30En, paraffin-embedded sections
were labeled with immunoperoxidase applying rabbit anti-
Figure 2 SCL, FLT1 and FLK1 gene expression following I/R
injury to murine kidneys. Quantitative RT-PCR was performed for
SCL, FLK1 and FLT1 at consecutive time points after ischemia.
Three mice were analyzed for each time point. Fold expression
(calculated as log10 of RQ) denotes the relative expression compared
with sham kidneys. Data were calculated as average7s.d. Significant
induction of SCL and FLK1 mRNA is noted with time: SCL, Po0.05,
48 h and 1w compared to time point 24 h; FLK1, Po0.05, 48 h, 1
week, 2 weeks and 1 m compared to time point 24 h. SCL, stem
cell leukemia.
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beta-galactosidase (Abcam, Cambridge, MA, USA; 1:2000,
overnight incubation) and secondary reagent system, DAKO
EnvisionTMþ System, HRP (DAKO, Glostrup, Denmark), using
DAB as chromogen.31 Nuclei were counterstained with
hematoxylin. Controls were performed by omitting the primary
b-galactosidase antibody or by substituting the primary anti-
bodies with goat IgG isotype.
Magnetic cell sorting
A double-step immunomagnetic staining technique was used to
target the hematopoietic fraction for the immunomagnetic
separation step following kidney digestion. The primary
antibody used was a mouse anti-CD45 PE (BD Pharmingen)
and the secondary antibody was anti-PE magnetic cell
sorting (MACS) microbeads (Miltenyi Biotec, Auburn, CA,
USA). At least three cycles of magnetic selection were
used for cell purification as previously described.31 For MACS,
the labeling was performed on 3–5 106 kidney cells
by incubating in PE-conjugated CD45 antibodies and a
second incubation in magnetic PE microbeads according to
the supplier (Miltenyi Biotech). For magnetic separation, we
used mini-MACS columns (Miltenyi Biotech), applying
3–5 106 labeled cells on one column.31 Both the positive
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Figure 3 Hematopoietic progenitor cell surface markers in the ischemic kidneys. Flow cytometry analysis of (a) pre-ischemic renal, (b) post-
ischemic renal and (c) spleen cell suspensions defines the renal ‘lymphogate’, with similar forward (FSC)/side scatter (SSC) parameters as
spleen cells. Within the ‘lymphogate’ the majority of cells (d, e; pre- and post-ischemic kidney, respectively) or all of the cells (f, spleen)
express the pan-hematopoietic marker CD45. (g–m) Analysis of hematopoietic cell surface marker expression within the renal ‘lymphogate’ in
intact (g, j, l) compared to ischemic (h, k, m) kidneys shows elevation in expression. (n) A representative image verifying the hematopoietic origin
of FLK1 (þ ) cells (double positive for CD45). (i) Isotype control. Percentage of total cells is shown in each panel. Experiments were repeated at
least three times.
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and negative fractions were applied to a second column before
subjecting the cells to FACS analysis.
Results
Origin of SCL 30En-expressing cells in the adult kidney
We have previously demonstrated that the high expression of
SCL during nephrogenesis is abrogated in the adult kidney.
Nevertheless, we could identify SCL 30En-expressing cells in the
adult renal interstitium.24 The SCL 30En driving b-galactosidase
as a reporter gene is detected in hematopoietic cells and
vasculature during development. However, a high degree of
variation in reporter gene expression is observed in the
vasculature of adult tissues, possibly due to the interaction of
the regulatory elements of the 30En and the lacZ reporter gene.23
To enhance the detection of all the potential kidney cells
expressing the SCL 30En, we used the SV/PLAP/19 transgenic
mice containing the þ 19 core enhancer element of the SCL
30En. This construct reproducibly directed strong expression in
adult hematopoietic and endothelial cells.23 Transgene expres-
sion can readily be detected in peripheral blood (Figure 1a,
middle panel). Detection of PLAP reporter gene by NBT staining
on transgenic kidney sections showed high level of expression in
the interlobular spaces, coinciding with the vascular network
(Figure 1c, middle panel). To determine the nature of SCL30En-
expressing cells, we performed triple staining immunofluores-
cence for PLAP, CD45 and CD31 molecules. While some of the
PLAPþ cells express CD45, the majority of PLAPþ cells are
negative for CD45 and of endothelial (CD31þ ) or more
fibroblastic appearance (CD31) (Figure 1d, upper panel).
Accordingly, three types of cell populations can be identified
CD45þCD31 hematopoietic cells, CD45CD31þ endothe-
lial cells and CD45CD31 interstitial cells. To determine if
SCL 30Enh cell subsets can be derived from the bone marrow,
we generated bone marrow chimeras by infusing SCL 30En bone
marrow cells obtained from SV/PLAP/19 transgenic mice into
pre-conditioned wild-type newborn hosts. FACS analysis of
peripheral blood for expression of the reporter gene PLAP
demonstrated stable chimerism at 5 months post transplant
(Figure 1a, right panel). Engraftment of bone marrow-derived
cells in the kidneys was analyzed in positive chimeras by
histochemistry and immunostaining for PLAP. We identified
cells of endothelial, fibroblastic and round blood morphology in
kidney sections from chimeric mice stained with NBT for PLAP
detection (Figure 1c, right panel). To further determine the
nature of these cells, we performed co-immunostaining for
PLAP, CD45 and CD31. Similarly, staining of chimeric kidneys
revealed PLAP-positive cells that coexpress CD45 as well as
PLAPþCD45CD31 and PLAPþCD45CD31þ cells
(Figure 1d, lower panel). Thus, all types of resident SCL 30Enþ
cells in the postnatal kidney can be derived from the bone
marrow. To determine whether contribution of transplanted
bone marrow cells into blood vessels following transplantation
represents a more widespread phenomenon, we performed
staining of the chimeric liver. To identify endothelial cells we
used isolectine B4,32 as CD31 could not be homogenously
identified in the liver sections (Figure 1e, upper panel). The few
donor-derived cells observed were predominantly localized
around big vessels of the portal area, mostly composed of
PLAPþCD45þ IsoB4 cells and few PLAPþCD45IsoB4þ
(Figure 1e, lower panel). We could only identify one fibroblastic
cell that was PLAPþCD45IsoB4 in the 20 donor-positive
liver fields, whereas this population was easily identified in the
chimeric kidney (Figure 1e, lower panel).
Having identified PLAPþCD45CD31 cells in the chi-
meric kidney, we determined whether donor bone marrow cells
contain a similar fraction (Figure 1b). Transgenic bone marrow
cell suspension analysis by FACS showed that the percentage on
PLAPþ not expressing blood markers (CD45/Ter119) is low,
around 0.1% (control not transgenic 0.0%). Both CD31þ (85%)
and CD31 (14%) can be identified within the PALPþCD45/
ter119 fraction (Figure 1b). Thus, although in a very small
proportion all three populations can be identified in the bone
marrow.
SCL, FLK1 and FLT1 mRNA expression in regenerating
kidneys
We next determined whether intra-renal SCL mRNA is induced
following I/R injury to the kidneys of SCL 30En transgenic mice.
Histopathology of adult kidneys 24–48 h after ischemia showing
lumen obliteration with loss of brush border as well as the
disappearance of nuclei and necrosis of tubular cells has been
previously demonstrated.28 We analyzed SCL transcript levels
along with the VEGF receptors FLK1 and FLT1, which have been
shown to participate in the angiogenesis of ischemic limb and
heart33 at consecutive time points after ischemic injury. Real-
time PCR demonstrated an early decline followed by rapid
upregulation of SCL mRNA, peaking 48 h after ischemia
(Figure 2). This response declined thereafter and transcript
levels returned to baseline at 2 weeks after ischemia. Similarly,
FLK1 showed an initial reduction in transcript levels followed by
significant elevation. In contrast to SCL, FLK1 mRNA continued
to increase and peaked at 4 weeks post-ischemia. FLT1 mRNA,
although mildly elevated at 1 week, did not achieve statistical
significance and returned to baseline levels afterwards. Thus,
ischemic injury induces rapid and transit induction of intra-renal
SCL mRNA followed by a prolonged and significant induction
of FLK1.
Elevation of hem-endothelial progenitor cells in the
ischemic kidney
To determine whether postnatal induction of SCL after ischemic
injury is associated with a systemic response involving recruit-
ment of subsets of cells into the kidney bearing hem-endothelial
progenitor markers, both ischemic and intact kidneys were
digested and analyzed by flow cytometry for the expression of
CD45, CD34, c-Kit and FLK1 at early (48 h) and late time points
(4 weeks) (Figure 3). Analysis of the cell suspension after the
addition of ACK for removal of RBCs in pre- and postischemic
Figure 4 In situ localization of lacZ/SCL 30En in kidneys subjected to I/R injury. Immunostaining for LacZ was performed on intact kidneys (a–d)
and kidneys 48 h after injury (e–h). (a) Basal expression of SCL LacZ/30En; magnification, 40. Expression is localized to endothelial-appearing
cells ((b) arrow, original magnification  40; (c) original magnification 100) and fibroblast-like cells ((b) arrowhead, original magnification
 40; (d) original magnification 100). (e) Expression of SCL 30En is more prominent in ischemic kidneys (magnification,  40), with similar
localization of LacZ to elongated cell types (f, original magnification 40), but also to clusters of more round cells residing in close proximity to
the renal tubules in the perivascular space (g and h, original magnification  40). Analysis of SCL 30En expression in the spleen of mice subjected
to I/R renal injury reveals prominent staining (i) compared to intact spleen (j), (i, j) magnification 40. SCL, stem cell leukemia.
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kidneys, and comparison to spleen showed a cluster of cells
compatible with lymphocytes, which were gated (‘lymphogate’)
(Figures 3a–c). CD45 expression in both kidneys and spleen is
clearly demonstrated in this gate (Figures 3d–f, respectively).
Nonspecific antibody binding estimated by isotype control
staining was approximately 0.3% (Figure 3i). While c-Kit, CD34
and FLK1 expression in intact kidneys was just above or below
that of isotype control (0.6%70.09, 0.4%70.066 and
0.3%70.07), we found that in ischemic counterparts,
1.32%70.14, 1.1%70.11 and 1.02%70.085 of the total cells
were positive for c-Kit, CD34 and FLK1, respectively (Po0.05 in
all instances) (Figures 3g–m). Moreover, most of the FLK1-
expressing cells were double positive for CD45 (Figure 3n).
These changes in cell composition within the renal ‘lymphogate’
were not observed at 4 weeks after I/R injury (data not shown).
Thus, acute ischemic injury results in the early increase of cells
expressing hematopoietic and endothelial progenitor markers in
the adult kidney.
Changes in SCL lacZ/30En (þ ) cells in the kidney
following I/R injury
Following the observation that I/R injury induces expression
of SCL mRNA and elevation of putative hem-endothelial
progenitor cells, we determined the in situ expression of SCL
30En in ischemic þ 6E5/lacZ/30En transgenic kidneys. We chose
to analyze the presence of b-galactosidase (LacZ) as the
advantages of LacZ immunostaining for reporter gene detection
specifically following I/R kidney injury have been recently
demonstrated.34 Also the reduced level of b-galactosidase-
expressing cells in SCL/lacZ/30En transgenic kidneys23
should allow detection of an increase in interstitial progenitor
SCL 30En-expressing cells.
As shown for the SV/PLAP/19 transgenic kidneys, we found
endogenous expression of SCL lacZ/30En in the intact adult
kidney (Figure 4a). Expression was mostly localized to cells
appearing as mature endothelial (Figures 4b (arrow) and c) and
fibroblast-like cells (Figures 4b (arrowhead) and d). At 48 h after
renal injury, immunostaining of the SCL 30En in the ischemic
kidneys was more prominent compared with control intact
kidneys. Similar to the intact kidneys, in the ischemic counter-
part, we found expression of LacZ in endothelial-appearing and
fibroblast-like cells (Figures 4e and f). However, more abundant
were interstitial round cells positively stained for SCL 30En.
These clusters of SCL 30En-positive cells were identified in the
ischemic kidney in close proximity to renal tubules in the
perivascular spaces (Figures 4g and h). Interestingly, I/R injury
resulted in increased SCL 30En expression in the spleen,
suggestive of a systemic response involving migration of SCL
30En (þ ) cells (Figures 4i and j).
To quantify the change in SCL 30En-expressing cells and to
determine whether hematopoietic or non-hematopoietic SCL
30En-expressing cells are elevated in the adult kidney after I/R
injury, we sorted the CD45 (þ ) hematopoietic fraction and the
CD45 () non-hematopoietic fraction from the adult kidney by
labeling cells with CD45-PE antibody and then applying the
MACS system with anti-PE microbeads (Figures 5a and b).
Immunostaining of the CD45 (þ ) sorted cells for LacZ and
counting the number of positive cells demonstrated that a very
small fraction of LacZ-expressing cells was present in the
suspension obtained from the native kidney (0.870.8 cells/
HPF 100) (Figures 5C). Analysis of the sorted fraction obtained
from injured kidneys, 48 h and 7 days post-ischemia, demon-
strated a significant elevation in the number of LacZ-expressing
cells (large nuclei, small cytoplasm), of approximately six-fold
(4.771.96 cells/HPF 100, P¼ 0.001), followed by decline in
cell number (Figures 5c and e). In contrast, immunostaining in
the CD45-negative fraction revealed significantly increased
LacZ (þ ) cells, bearing larger cytoplasm, only at 7 days after
I/R injury (2.571.2 vs 1.270.64 cells/HPF 100, P40.05)
(Figures 5d and f). This elevation was modest compared to that
observed for the hematopoietic cells. Thus, I/R injury induces
rapid elevation of SCL 30En-positive cells of hematopoietic
origin.
Discussion
Reporter gene expression driven by the SCL 30En characterizes
the bipotential embryonic mesodermal progenitor, the heman-
gioblast, which gives rise to blood and blood vessels.13,35 In
adult life, bone marrow contains endothelial precursors with
phenotypic and functional characteristics of embryonic heman-
gioblasts.36 Given that SCL functions in hem-endothelial
differentiation, it was surprising to find resident interstitial SCL
30En-expressing cells in the adult kidney.24 We now character-
ized these cells among which are hematopoietic (CD45þ
CD31), mature endothelial (CD45CD31þ ), and surprisingly
a relatively large fraction of nonendothelial non-hematopoietic
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Figure 5 Increase in the number of SCL 30En cells in ischemic
kidneys. MACS sorting was performed on cell suspension from intact
and ischemic kidneys separating hematopoietic CD45 (þ ) and non-
hematopoietic CD45 () cell fractions. FACS analysis of the sorted
fractions showing enriched (a) CD45-expressing hematopoietic
population and (b) cell fraction lacking CD45. Immunostaining of
these cell fractions for lacZ/SCL 30En (5 high-power fields/kidney in
three kidneys of each group) demonstrates (c and d) significant
increases in the number of SCL 30En-positive cells within the CD45
(þ ) and CD45 () cell fractions at 48 h (CD45þ ) and 7 days (CD45)
after renal I/R injury. In ischemic kidneys, positively stained cells in
the CD45 (þ ) fraction appear as mononuclear (large nuclei, small
cytoplasm) (e, original magnification  100) and in the CD45 ()
fraction as bearing larger cytoplasm (f, original magnification  100).
FACS, fluorescence-activated cell sorting; MACS, magnetic cell
sorting; SCL, stem cell leukemia.
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cells (CD45CD31). Because only SCL 30EnþCD45þ cells
were observed in the peripheral blood, the latter do not
represent circulating cells. In addition, all types of intra-renal
SCL 30En (þ ) cells can be traced back to a bone marrow origin,
using genetic tagging in bone marrow chimeric mice, supporting
the idea that at least some of the SCL 30En cells, including the
CD45-negative population, are not of intrinsic renal origin.
Although in a very small proportion, all three populations of SCL
30En-expressing cells can be identified in the bone marrow,
indicating that the different fractions of intra-renal SCL 30En (þ )
cells may be derived from three different types of progenitors in
the bone marrow (that is hematopoietic stem cells , angioblasts
and mesenchymal stem cells). Currently, we cannot discrimi-
nate if these populations expand or differentiate from a single
progenitor population, such as the HSCs, previously identified in
the PLAPþ fraction.23
Clearly, the bone marrow contributed to formation of mature
endothelial cells in peri-tubular capillaries of the kidney,
representing postnatal vasculogenesis. Identification of donor-
derived endothelial cells in the liver suggesting that this
phenomenon is widespread and not limited to the kidney is in
agreement with previous reports.37 Nevertheless, the near
absence of bone marrow-derived SCL30En þ population
negative for blood and endothelial markers in the chimeric
liver demonstrates this fraction to be specifically associated with
the kidney.
The finding of resident SCL 30En (þ ) cells in the kidney
that lack hem-endothelial differential markers is intriguing.
One possibility is that the PLAPþCD31CD45 cells
are myofibroblastic cells as the SCL30En is also expressed in
vascular smooth muscle cells associated to big vessels in
the kidney.38 Indeed, analysis by immunofluorescence showed
clear coexpression of the muscle-associated antigen a-actin
and PLAP in arteries (data not shown). However, a-actin
expression was almost undetectable in the capillary network
of the kidney, supporting the idea that the CD45PLAPþ
cells are not of muscular nature. We favor the idea that these
cells may signify local angioblastic/hemangioblastic progenitors
that have migrated from areas of blood formation during
development14 and in adulthood from the bone marrow.
This observation would parallel findings in skeletal muscle
connective tissue where resident progenitor cells, shown to
promote neovascularization, were tracked back to a bone
marrow origin.39
Recent studies have addressed the roles of bone marrow-
derived progenitor cells in the repair of ischemic injured
kidneys.40,41 While the ability of bone marrow cells to
repopulate renal tubular cells is controversial,34 contribution
to repair of endothelial injury seems more promising. We have
recently suggested a role for human CD34þ hematopoietic
stem cells (enriched for the endothelial progenitor marker
CD133) in vasculogenesis and not tubulogenesis, after their
engraftment in ischemic murine kidneys.28 Similar findings of
peri-tubular vascularization were reported in postischemic
kidneys34 and more progressive renal injury.42 Furthermore, in
a different model system, Rookmaaker et al.27 induced murine
experimental glomerulonephritis and showed that whole murine
bone marrow-derived cells (not fractioned into stem cell
subtypes) participates in endothelial repair in injured glomeruli.
In addition, intrarenal injection of culture modified bone
marrow-derived angiogenic cells reduced endothelial injury in
experimental glomerulonephritis.43 Thus, the vasculogenic
potential of bone marrow-derived cells, previously shown in
heart infarct or retinal neovascularization,44,45 can be demon-
strated in injured kidneys.
All these studies however did not examine the involvement of
endogenous hematopoietic-angioblastic progenitors after renal
injury. We show that acute I/R results in rapid induction of SCL
mRNA followed by the VEGF receptor FLK1. These results are in
agreement with previous studies showing SCL as an upstream
transcriptional regulator of Flk-1,17 suggesting that the transient
expression of SCL possibly induces the sustained expression of
FLK1. SCL induction is associated with the elevation of cells
expressing hematopoietic/endothelial progenitor markers and
SCL 30En-expressing cells in the kidney. Immunostaining
showing accumulation of round SCL 30En (þ ) cells in the
interstitial spaces and cell sorting of the CD45 cell fraction
suggests a rapid influx of hematopoietic-angioblastic progenitors
after renal injury. Thus, while in the intact kidney CD45þ SCL
30En(þ ) cells represent a small fraction of the SCL 30En-
expressing cells, they predominate in the early phase after
ischemia (48 h). The recently documented SDF-1a/CXCR4
gradient promoting migration of blood and marrow cells into
the ischemic kidney supports these findings.46
However, it is also possible that the intra-renal bone marrow-
derived SCL 30En (þ ) cells present in the intact adult kidney are
induced to proliferate after ischemic injury, resulting in SCL
induction. This is more likely to be relevant to the non-
hematopoietic SCL 30En (þ ) cells, which showed a modest but
significant increase in number a week after ischemia. It will be
of interest to determine if there is a distinct functional difference
and role for the previously resident SCL 30En (þ ) cells in the
kidney versus the influx of SCL 30En (þ ) cells from the bone
marrow. Interestingly, Brunet de la Grange et al.47 have
revealed a major role for SCL in specification of adult
hematopoietic myeloid progenitors, a type of hematopoietic
cell that has been recently shown to stimulate angiogenesis in
adult tissues via secretion of angiogenic growth factors.48
Indeed, Huss et al.49 showed that intravenous infusion of
SCL(þ ) multipotent adult progenitor cell clones in a hind-limb
ischemia transplant model supported muscle repair via en-
hanced local arteriogenesis rather than induction of new blood
vessel formation. In this regard, further characterization,
purification and functional analyses of specific SCL 30En cell
subsets could be informative.
Finally, considering into that SCL 30 enhancer is dispensable
for hematopoietic development,50 it remains to be determined
whether the observed 30 enhancer-mediated upregulation of SCL
in injured kidneys is mandatory for vascular repair.
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